Wed, Nov 26, 2014, 11:41 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ANI Pharmaceuticals, Inc. Message Board

  • kmanelson kmanelson Mar 29, 2010 11:29 PM Flag

    GNVC

    GenVec Discontinues Phase 3 Clinical Trial of TNFerade(TM)

    http://www.reuters.com/article/idCAN2911300020100329?rpc=44

    Looks like another phase 3 trial relating to pancreatic cancer bit the dust. This reminded me of what happened to GVAX when it was in phase 3 clinical trials for prostate cancer. Hopefully, it'll do better in the pancreatic and leukemia trials.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • It's the Panc trial starting soon that will be of most interest to you...FWIW,I now believe GVAX has been licensed...Just guessing wildly folks***

    • Active, not recruiting GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
      Condition: Prostate Cancer
      Intervention: Biological: GM-CSF gene transduced allogeneic vaccine GVAX
      ...............................

      Active, not recruiting GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies
      Conditions: Myelodysplastic Syndrome RAEB-I or RAEB-II; Refractory Acute Myeloid Leukemia; Refractory CML Myeloid Blast Crisis
      Intervention: Biological: GM-CSF secreting leukemia vaccine
      .........................................

      Active, not recruiting Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Bronchoalveolar Lung Cancer
      Condition: Lung Cancer
      Intervention: Biological: GVAX lung cancer vaccine

      ...............................................................
      Active, not recruiting Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
      Conditions: Sarcoma, Clear Cell; Sarcoma, Alveolar Soft Part; Renal Cell Carcinoma; Melanoma
      Intervention: Biological: GVAX
      ......................................
      ......................................
      PS: NOT YET RECRUITING AND RECRUITING

      Not yet recruiting Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
      Condition: Prostate Cancer
      Interventions: Biological: GVAX prostate cancer vaccine; Drug: bicalutamide; Drug: goserelin; Drug: leuprolide acetate


      Recruiting Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
      Condition: Pancreatic Cancer
      Interventions: Biological: GVAX pancreatic cancer vaccine; Drug: cyclophosphamide

    • Someone on this board recommended GNVC when it was in the .70's...I bought 10k shares and sold it at a very small gain. This is a real shame that another cancer vaccine blows up and retail investors lose money.

      Fin,
      Do you remember who was recommending GNVC?

      GLTA

      • 1 Reply to mthsbth
      • Beth;can't remember that guy's name but I know who you are talking about...I bought at .83,watched it go to over 3$,got out around even...It is truly a shame;it had great promise to bring inoperable panc to the surgical option...
        Gemzar/5FU with radiation can achieve this but in very small numbers...
        Hopefully the new GVAX with ipilimumab will show better results at JH in this population...
        I was truly hoping TNFerade/GVAX could be the 1-2 punch against this disease...but there still is a good chance for the 20% or so who have surgery that the vax can prevent recurrence...You will see promising p2 results shortly...

    • Ouch. I lost some but will hold until the dust settles. I did get in right after dilution at $1.80. A lot of people lost their shirts on that one.

      People will set stops at $2 and the market will open at 0.45 cleaning up all the shares. Watched this happen at CTIC. I might throw out an order for 0.45 and watch it go up to a buck later in the day then sell it if it fills.

 
ANIP
55.41+0.23(+0.42%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
SeaDrill Limited
NYSEWed, Nov 26, 2014 4:01 PM EST
KLA-Tencor Corporation
NasdaqGSWed, Nov 26, 2014 4:00 PM EST
TASER International Inc.
NasdaqGSWed, Nov 26, 2014 4:00 PM EST